Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death

Abstract

Studies aimed at examining the precise function(s) of the retinoblastoma tumor suppressor protein, RB, have been hindered by the rapid phosphorylation and inactivation of ectopically expressed RB which occurs in the majority of cell types. Therefore, ectopically expressed RB is a poor inhibitor of cellular proliferation. We have designed constitutively active RB proteins, PSM-RB, that cannot be inactivated by phosphorylation. Using these proteins, we show that unlike wild-type RB, PSM-RB proteins inhibit cell cycle progression in a broad range of tumor cell types. Furthermore, unlike p16ink4a, PSM-RB is also a potent inhibitor of cell cycle progression in RB-deficient tumor cells. Surprisingly, we identified a tumor cell line that is resistant to the cell cycle inhibitory effects of PSM-RB. This finding challenges the hypothesis that RB must be inactivated in all cells for cell cycle progression to occur. Further characterization of this ‘resistant’ tumor line revealed that proliferation of these cells is still inhibited by PSM-RB. We show that this is due to PSM-RB-induced cell death. As such, these studies are the first to show that RB inhibits cellular proliferation through at least two distinct mechanisms – inhibition of cell cycle progression and induction of cell death.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Antelman D, Perry S, Hollingsworth R, Gregory RJ, Driscoll B, Fung YK and Bookstein R. . 1997 Oncogene 15: 2855–2866.

  • Bartek J, Bartkova J and Lukas J. . 1997 Exp. Cell Res. 237: 1–6.

  • DePinho RA. . 1998 Nature 391: 533, 535–536.

  • Hoshikawa Y, Mori A, Amimoto K, Iwabe K, and Hatekeyama M. . 1998 Proc. Natl. Acad. Sci. USA 95: 8574–8579.

  • Knudsen ES, Buckmaster C, Chen TT, Feramisco JR and Wang JY. . 1998a Genes Dev. 12: 2278–2292.

  • Knudsen ES, Pazzagli C, Born T, Bertolaet B, Knudsen KE, Arden KC, Henry R and Feramisco JR. . 1998b Cancer Res. 58: 2042–2049.

  • Knudsen KE, Arden KC and Cavenee WK. . 1998c J. Biol. Chem. 273: 20213–20222.

  • Knudsen ES and Wang JY. . 1997 Mol. Cell. Biol. 17: 5771–5783.

  • Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J. . 1995 Nature 375: 503–506.

  • Qin XQ, Chittenden T, Livingston DM and Kaelin WG Jr. . 1992 Genes Devel. 6: 953–964.

  • Sherr CJ. . 1996 Science 274: 1672–1677.

  • Sidle A, Palaty C, Dirks P, Wiggan O, Kiess M, Gill RM, Wong AK and Hamel PA. . 1996 Critical Reviews in Biochem. Mole. Biol. 31: 237–271.

  • Templeton DJ, Park SH, Lanier L and Weinberg RA. . 1991 Proc. Natl. Acad. Sci. USA 88: 3033–3037.

  • Trouche D, Le Chalony C, Muchardt C, Yaniv M and Kouzarides T. . 1997 Proc. Natl. Acad. Sci. USA 94: 11268–11273.

  • Wang JY. . 1998 Trends Cell Biology 8: 116–120.

  • Wang JY, Knudsen ES and Welch PJ. . 1994 Cancer Res. 64: 25–85.

  • Weinberg RA. . 1995 Cell 81: 323–330.

  • Welch PJ and Wang JY. . 1993 Cell 75: 779–790.

  • Whitaker LL, Su H, Baskaran R, Knudsen ES and Wang JY. . 1998 Mole. Cell. Biol. 18: 4032–4042

  • Zacksenhaus E, Bremner R, Jiang Z, Gill RM, Muncaster M, Sopta M, Phillips RA and Gallie BL. . 1993 Cancer Res. 61: 115–141.

  • Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N and Harlow E. . 1993 Genes Devel. 7: 1111–1125.

Download references

Acknowledgements

The authors thank Dr JYJ Wang (UCSD, Biology and Cancer Center) for inspired discussion and initial support of this project. Drs G Wahl and T Kendo (Salk Institute) for the generous gift of the plasmid encoding H2B-GFP. We also thank C Buckmaster for logistical support. KE Knudsen is supported by a postdoctoral fellowship from the National Cancer Institute (CA82034). E Weber was supported by the Swiss National Foundation. This work was also supported by a grant to JR Feramisco from the California Tobacco Related Disease Research Program and a grant to ES Knudsen from American Cancer Society (ACS-IRG189). ES Knudsen is a Kimmel Scholar.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knudsen, K., Weber, E., Arden, K. et al. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene 18, 5239–5245 (1999). https://doi.org/10.1038/sj.onc.1202910

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202910

Keywords

This article is cited by

Search

Quick links